Irrational Exubera-nce for Pfizer?

The outfit's inhaled insulin may not be the revolutionary treatment many expect. If that proves to be the case, expect insurance companies to balk

Investors cheered when, on Jan. 27, the U.S. Food & Drug Administration approved Pfizer's Exubera, the first inhaled insulin therapy to reach the market. The general consensus among analysts is that Exubera is likely to be a blockbuster.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.